36 related articles for article (PubMed ID: 38669754)
1. Current status and quality of radiomic studies for predicting KRAS mutations in colorectal cancer patients: A systematic review and meta‑analysis.
Jia LL; Zhao JX; Zhao LP; Tian JH; Huang G
Eur J Radiol; 2023 Jan; 158():110640. PubMed ID: 36525703
[TBL] [Abstract][Full Text] [Related]
2. Comments on "Current status and quality of radiomic studies for predicting KRAS mutations in colorectal cancer patients: A systematic review and meta-analysis".
Fusco R; Granata V
Eur J Radiol; 2023 Dec; 169():111192. PubMed ID: 37976763
[TBL] [Abstract][Full Text] [Related]
3. Using tumor habitat-derived radiomic analysis during pretreatment
Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
[TBL] [Abstract][Full Text] [Related]
4. Preoperative prediction of KRAS mutation status in colorectal cancer using a CT-based radiomics nomogram.
Xue T; Peng H; Chen Q; Li M; Duan S; Feng F
Br J Radiol; 2022 Jun; 95(1134):20211014. PubMed ID: 35312376
[TBL] [Abstract][Full Text] [Related]
5. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
6. Response to letter by Fusco Roberta & Vincenza Granata-Re: Comments on "Current status and quality of radiomic studies for predicting KRAS mutations in colorectal cancer patients: A systematic review and meta‑analysis".
Jia LL; Lei J
Eur J Radiol; 2024 Jun; 175():111195. PubMed ID: 38669754
[No Abstract] [Full Text] [Related]
7. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.
Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA
Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037
[TBL] [Abstract][Full Text] [Related]
8. Radiomics in precision medicine for gastric cancer: opportunities and challenges.
Chen Q; Zhang L; Liu S; You J; Chen L; Jin Z; Zhang S; Zhang B
Eur Radiol; 2022 Sep; 32(9):5852-5868. PubMed ID: 35316364
[TBL] [Abstract][Full Text] [Related]
9. Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects.
Ma JW; Li M
Transl Cancer Res; 2021 Sep; 10(9):4217-4231. PubMed ID: 35116717
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.
Westwood M; van Asselt T; Ramaekers B; Whiting P; Joore M; Armstrong N; Noake C; Ross J; Severens J; Kleijnen J
Health Technol Assess; 2014 Oct; 18(62):1-132. PubMed ID: 25314637
[TBL] [Abstract][Full Text] [Related]
11. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL
Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
